PREECLAMPSIA DIAGNOSTICS MARKET ANALYSIS

Preeclampsia Diagnostics Market Size and Trends

Global preeclampsia diagnostics market is estimated to be valued at USD 2.10 Bn in 2024 and is expected to reach USD 4.12 Bn 2031, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2024 to 2031.

To learn more about this report, request sample copy

Global preeclampsia diagnostics market is expected to witness growth over the forecast period due to rising prevalence of preeclampsia among expectant. According to World Health Organization (WHO), hypertensive disorders during pregnancy affects 5-8% of all pregnancies globally and preeclampsia is a common complication responsible for significant number of maternal and fetal morbidity and mortality cases worldwide each year. Moreover, growing awareness regarding preeclampsia diagnosis and management and increasing access to advanced healthcare facilities in developing countries can present lucrative growth opportunities for players in preeclampsia diagnostics market. However, availability of alternative treatment options and lack of point-of-care diagnostic kits in low-income countries may hamper the market growth during the forecast period.

Rising preeclampsia cases globally

Rising preeclampsia cases globally can drive the global preeclampsia diagnostics market growth. Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system. It is a leading cause of maternal and neonatal morbidity and mortality worldwide. According to the World Health Organization (WHO), preeclampsia complicates approximately 5-8% of all pregnancies worldwide annually. According to the WHO in 2020, preeclampsia is responsible for 76,000 maternal and 500,000 fetal deaths globally every year. Increasing number of preeclampsia cases poses a huge clinical and economic burden on healthcare systems internationally. For instance, in August 2022, Mayo Clinic researchers, a nonprofit organization committed to clinical practice, found that women with a history of severe preeclampsia show more markers of brain cell damage and inflammation compared to those with uncomplicated pregnancies. These findings, presented at the Alzheimer's Association International Conference, suggest long-term effects of preeclampsia beyond pregnancy. Preeclampsia, affecting up to 15% of women, can lead to serious complications for both mother and baby if untreated. It is linked to increased risks of heart disease, stroke, and cognitive decline later in life, with no reliable early markers available. The study explored whether circulating extracellular vesicles containing brain cell membranes could be detected in women years after experiencing preeclampsia.

Increasing awareness and screening for preeclampsia

Rising awareness about preeclampsia and the health risks associated with it compels  women to opt for regular screening and tests during pregnancy. Medical professionals and health organizations have been highlighting the importance of screening pregnant women for signs and symptoms of preeclampsia. These emphasize that early detection can help receive timely treatment and manage the condition well. Various national programs are also conducted to educate expectant mothers about underlying conditions, testing options, and managing comprehensive care.

Several new guidelines by reputed medical bodies now recommend screening protocols and tests schedules for all pregnant women based on their risk factors. This includes monitoring of blood pressure at every visit and checking for protein in urine samples at specific intervals. Detection of even mild symptoms is prompting doctors to conduct advanced tests like blood tests, ultrasounds to measure kidney function, blood platelet count, and fetal growth. Special attention is being paid to high-risk pregnancies owing to chronic conditions, multiple births, obesity, or a prior history of preeclampsia. All these efforts have certainly increased the number of tests being conducted per pregnancy.